NEW YORK ─ Italian startup Diadem is looking to take on an obstacle in the ability to treat Alzheimer's disease: the lack of diagnostic tests that can detect early-stage disease to slow down its progression.
Based in Milan, the company plans to launch its AlzoSure blood-based test that uses an antibody to target changes in the p53 protein. Specifically, the test detects unfolded p53, a conformational change of P53 that reflects the production of amyloid beta in the brain, Diadem's newly appointed CEO Paul Kinnon said in an interview.